

Cigall Kadoch, Ph.D., is an Associate Professor of Pediatric Oncology at Dana-Farber Cancer Institute, a Howard Hughes Medical Institute Investigator, and an Institute Member and Epigenomics Program Co-Director at the Broad Institute of MIT and Harvard.

She established her independent laboratory in 2014, at age 28, one of the youngest scientists ever appointed to the Harvard Medical School faculty, immediately following completion of her Ph.D. studies in Cancer Biology at Stanford University working with developmental biologist Gerald Crabtree. She has quickly become a leading expert in chromatin and gene regulation and is internationally recognized for her groundbreaking studies in these areas. Specifically, her laboratory studies the structure and function of chromatin remodeling complexes such as the mammalian SWI/SNF (or BAF) complex, with emphasis on defining the mechanisms underlying cancer-specific perturbations. Of note, the recent surge in exome- and genome-wide sequencing efforts has unmasked the major, previously unappreciated contribution of these regulators to malignancy: indeed, the genes encoding subunits of mammalian SWI/SNF complexes are mutated in over 25% of human cancers.

Dr. Kadoch has received numerous prestigious awards and research grants to support her academic laboratory at Harvard, including the NIH Director's New Innovator Award, the Pew Scholar Award, the American Cancer Society Research Scholar Award, and, most recently, the American Association for the Advancement of Science (AAAS) Martin and Rose Wachtel Cancer Research Prize. Additionally, she was named to the *Forbes* 30 Under 30 list, *MIT Technology Review* 35 Innovators Under 35, *Popular Science* Brilliant 10, and *Business Insider* Top 30 Young Leaders in Biopharma.